Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
A letter from the PPMI Steering Committee regarding the status of CSF Data.
A new funding opportunity for research into both Parkinson’s and Alzheimer’s has been launched. The Michael J. Fox Foundation, the Alzheimer’s Association and The W. Garfield Weston Foundation have launched a new grant program to inspire scientists to envision research projects that will use existing data and/or biological samples from PPMI and another large-scale biomarker study, the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
A request for PPMI biospecimens has recently been approved by the Biospecimen Review Committee (BRC). The researchers at the University of Salerno will investigate the utility of IGF-1 levels and dopamine transporter (DaT) uptake as a biomarker for cognitive dysfunction in early PD by measuring IGF-1 in serum samples and analyzing DaT imaging data from 400 PD and 200 healthy control subjects at baseline.
Many of you in the scientific community have benefited from being able to access the enormous amount of data and specimens being collected as a result of the enormous contribution of over 650 PPMI participants, who have committed to the rigorous battery of tests and assessments involved in PPMI. To recognize the enormous contribution PPMI participants are making, the PPMI team and The Michael J. Fox Foundation collected letters from the Parkinson’s community, patients, family members, caregivers and researchers, thanking them for their tremendous contribution to Parkinson’s research.
An inventory of available biospecimens in PPMI can now be accessed on www.ppmi-info.org. This regularly updated table reflects the number of samples that are currently available for analysis by visit and type of sample. This is a key tool for researchers looking to request specimens to be analyzed for biomarker verification studies. This inventory table now provides researchers with real-time numbers of specimens available before submitting a request.